Autoimmune Diseases Diagnostics Market Outlook
The Global Autoimmune Diseases Diagnostics Market is projected to reach approximately US$ 8.64 Billion by 2030, according to Renub Research. Autoimmune diseases encompass a range of conditions where the immune system erroneously targets the body’s own cells, tissues, and organs, leading to inflammation and damage. There are over 80 recognized autoimmune diseases, including rheumatoid arthritis, lupus, and type 1 diabetes, impacting millions of individuals worldwide. The exact causes of these diseases are often unclear and involve a complex interplay of genetic and environmental factors. Symptoms can vary significantly, affecting multiple systems and organs. Diagnosing autoimmune diseases can be complex and often necessitates specialized tests. Treatment typically focuses on managing symptoms and modulating the immune response to enhance the patient’s quality of life.
As reported by NCBI, around 5% of the global population suffers from autoimmune disorders, which are chronic and varied in nature, and their prevalence is steadily rising, especially in Westernized nations. Immune responses targeting self-antigens can ultimately lead to cell destruction and the onset of autoimmune diseases. Despite being relatively rare, the incidence and prevalence of these conditions are increasing globally, with significant implications for both mortality and morbidity.
Market Growth Projections
The Global Autoimmune Diseases Diagnostics Market is expected to grow at a CAGR of 7.17% between 2024 and 2030. The aging global population, which is particularly vulnerable to autoimmune diseases, is driving growth in the diagnostics market. This demographic shift creates an expanding phase for diagnostics, fostering increased market growth. The market is witnessing the introduction of new biomarkers and tests for rarer autoimmune diseases, addressing the diverse needs of patients. The rise in healthcare expenditures, bolstered by enhanced public and private funding worldwide, further supports this growth. Increased insurance coverage is also improving access to diagnostics, making tests available to a broader population, thereby creating a thriving market environment with a variety of services and financial support.
Growing awareness is prompting early consultations for autoimmune diseases, leading to increased demand for specialized diagnostics and tailored treatment plans. The use of autoantibody assays, genetic testing, imaging, and diagnostics provides precise results. Robotics in laboratories and point-of-care testing enhance accessibility. Additionally, advancements in AI are enabling accurate predictions of disease risks, paving the way for personalized treatment options. In the United States, the autoimmune disease diagnostics market is anticipated to see significant growth driven by new product introductions and the presence of key companies, contributing to the market’s expected expansion during the forecast period. As a result, the Global Autoimmune Diseases Diagnostics Market was valued at US$ 5.32 Billion in 2023.
Market Segmentation
Diagnostics Equipment Dominates
The global autoimmune diseases diagnostics market is segmented by product into Therapeutic & Monitoring Equipment, Diagnostics Equipment, and Drugs. Accurate and timely diagnosis is crucial for managing autoimmune diseases. Diagnostics equipment, ranging from blood analyzers to imaging systems, plays a key role in early detection, improving outcomes. The market offers a wide array of tests, including specialized imaging, to cater to varying needs. Technological advancements, such as AI and automation, are driving market growth. The rising incidence of autoimmune diseases fuels demand for innovative solutions. Personalized treatment relies on accurate diagnoses, while supportive regulations and insurance coverage improve accessibility. Streamlined workflows and automation minimize errors, and early intervention capabilities enhance disease prevention.
Systemic Autoimmune Diseases Lead the Market
The global autoimmune diseases diagnostics market is further divided into Systemic Autoimmune Disease Diagnostics and Localized Autoimmune Disease Diagnostics. Systemic autoimmune diseases (SADs) contribute significantly to morbidity and mortality, often requiring lifelong treatment and monitoring, which drives the demand for specialized diagnostics. Key advancements, including highly accurate autoantibody assays, genetic testing for susceptibility markers, and advanced imaging techniques, improve diagnostic accuracy and efficiency, thus supporting market growth. Early detection is critical for effective management of SADs, reducing disease progression and organ damage, which in turn fosters demand for accessible and accurate diagnostic tools. Increased awareness of SADs and their implications is leading more individuals to seek medical attention and screening tests, further stimulating market expansion.
Rheumatic Disease Diagnostics Hold a Significant Share
The global autoimmune diseases diagnostics market is categorized by indication into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Others. Rheumatic diseases, affecting 1 in 4 adults globally, create a substantial demand for diagnostics. Various subtypes, such as rheumatoid arthritis and lupus, require precise diagnostic methods, driving the development of a wide range of tests. The complexity of diagnosis, characterized by overlapping symptoms, necessitates advanced techniques like autoantibody assays and genetic testing. Early detection is essential for effective management and preventing joint damage. Research focuses on innovative diagnostics equipment to enhance accuracy and facilitate personalized medicine, highlighting the importance of precise diagnostics in predicting disease progression and informing interventions.
End-User Insights
Diagnostics Centers Expected to Lead
By end-user, the global autoimmune diseases diagnostics market is divided into Hospitals, Diagnostics Centers, and Others. Specialized diagnostics centers excel in autoimmune disease testing, utilizing targeted expertise to provide faster and more accurate diagnoses with advanced technology. These centers emphasize patient satisfaction, offering cost-effective and conveniently located services aligned with value-based care. Collaborations with primary care physicians streamline referrals, ensuring appropriate testing is conducted. Integrated digital systems enhance efficiency. With the rise of outpatient services, diagnostics centers are becoming pivotal in diagnosing and managing autoimmune diseases, playing an essential role in the evolving healthcare landscape.
Regional Analysis
Asia-Pacific: A Key Player in Market Growth
The global autoimmune diseases diagnostics market is divided regionally into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand), Latin America (Brazil, Mexico, Argentina), and Middle East & Africa (South Africa, Saudi Arabia, UAE). The Asia-Pacific region, home to over half of the global population, faces a rising burden of autoimmune diseases. According to the Arthritis Foundation of Asia, approximately 47% of diabetes and 49% of heart patients are diagnosed with arthritis. The region’s adoption of cost-effective diagnostic solutions and increasing disposable incomes enhance access to diagnostics, driving market growth. Strategic initiatives, such as Avesthagen Limited’s partnership with Wipro Limited in June 2022 to commercialize genetic testing in India, also contribute to market expansion. Collaborations like these are expected to further strengthen market growth in the region.
Related Report :
Global Rapid Acting Insulin Market
Key Players
The global autoimmune diseases diagnostics market includes key companies such as Abbott Laboratories, Bio-Rad Laboratories, Roche Diagnostics, Siemens Healthineers, Bio Merieux SA, Myriad Genetics, Inc., Quest Diagnostics Incorporated, and Thermo Fisher Scientific Inc..
In August 2022, KSL Beutner Laboratories developed a blood test to detect an antigen linked to mucous membrane pemphigoid (MMP), an autoimmune blistering disease that often results in painful oral lesions. In May 2022, Thermo Fisher’s Phadia 2500+ instruments were set to provide reliable, high-throughput solutions for allergy diagnostics and autoimmune testing in the United States.
Product – Global Autoimmune Diseases Diagnostics Market breakup in 3 viewpoints:
1. Therapeutic & Monitoring Equipment
2. Diagnostics Equipment
3. Drugs
Types – Global Autoimmune Diseases Diagnostics Market breakup in 2 viewpoints:
1. Systemic Autoimmune Disease Diagnostics
2. Localized Autoimmune Disease Diagnostics
Indication – Global Autoimmune Diseases Diagnostics Market breakup in 5 viewpoints:
1. Rheumatic Disease
2. Diabetes
3. Multiple Sclerosis
4. Inflammatory Bowel Disease
5. Others
End-Users – Global Autoimmune Diseases Diagnostics Market breakup in 3 viewpoints:
1. Hospitals
2. Diagnostics Centers
3. Others
Countries – Global Autoimmune Diseases Diagnostics Market of 25 Countries
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Developments
• Revenue Analysis
Company Analysis:
1. Abbott Laboratories
2. Bio-Rad Laboratories
3. Roche Diagnostics
4. Siemens Healthineers
5. Bio Merieux SA
6. Myriad Genetics, Inc.
7. Quest Diagnostics Incorporated
8. Thermo Fisher Scientific Inc.
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://linkedin.com/company/renub-research
Website: www.renub.com
